Sign In
Buy RIGL
$30.30
+0.280 (+0.93%)
At Close: Jun 03, 2026
Why Did the FDA Reject Rigel's EUA Application for Its COVID-19 Therapy?
07:31am, Thursday, 26'th Aug 2021
More data is needed.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Rigel Pharmaceuticals, Inc. - RIGL
06:03pm, Tuesday, 17'th Aug 2021
New York, New York--(Newsfile Corp. - August 17, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Rigel Pharmaceuticals, Inc. ("Rigel" or the "Company") (NASDAQ: RIGL). Such inv
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Rigel Pharmaceuticals, Inc. - RIGL
04:30pm, Monday, 16'th Aug 2021
NEW YORK, Aug. 16, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Rigel Pharmaceuticals, Inc. ("Rigel" or the "Company") (NASDAQ: RIGL). Such investors are
Rigel (RIGL) COVID-19 Treatment Denied By FDA for EUA
12:59pm, Monday, 16'th Aug 2021
Rigel Pharmaceuticals' (RIGL) fostamatinib does not get the FDA's nod for emergency use for COVID-19. The company plans to submit data from a larger study.
Rigel Stock Falls After Update From COVID-19 Program
08:20am, Friday, 13'th Aug 2021
The FDA has informed Rigel Pharmaceuticals Inc (NASDAQ: RIGL) that data submitted in May from fostamatinib Phase 2 trial for COVID-19 is insufficient for an emergency use authorization (EUA). Rige
Rigel Pharmaceuticals Provides Update on COVID-19 Program
07:30am, Friday, 13'th Aug 2021
SOUTH SAN FRANCISCO, Calif., Aug. 13, 2021 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), today announced that the U.S. Food and Drug Administration (FDA) has informed the Company that c
Implied Volatility Surging for Rigel Pharmaceuticals (RIGL) Stock Options
11:00am, Wednesday, 11'th Aug 2021
Investors need to pay close attention to Rigel Pharmaceuticals (RIGL) stock based on the movements in the options market lately.
Rigel Pharmaceuticals, Inc. (RIGL) CEO Raul Rodriguez on Q2 2021 Results - Earnings Call Transcript
11:36pm, Tuesday, 03'rd Aug 2021
Rigel Pharmaceuticals, Inc. (RIGL) CEO Raul Rodriguez on Q2 2021 Results - Earnings Call Transcript
Rigel Pharmaceuticals (RIGL) Reports Q2 Loss, Tops Revenue Estimates
07:04pm, Tuesday, 03'rd Aug 2021
Rigel (RIGL) delivered earnings and revenue surprises of 27.27% and 18.96%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Rigel Pharmaceuticals (RIGL) Q2 Earnings Expected to Decline
04:05pm, Tuesday, 27'th Jul 2021
Rigel (RIGL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Rigel Announces Conference Call and Webcast to Report Second Quarter 2021 Financial Results and Business Update
07:30am, Tuesday, 27'th Jul 2021
SOUTH SAN FRANCISCO, Calif., July 27, 2021 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today announced that it will report its second quarter 2021 financial results after market close
3 Biotech Stocks That Could Rocket Higher
06:37am, Saturday, 24'th Jul 2021
Over the past year, these small-cap drugmakers have done well by their shareholders, and more big catalysts could be coming.
New TAVALISSE® Data Analyses To Be Presented at International Society on Thrombosis and Haemostasis (ISTH) 2021 Congress
07:30am, Wednesday, 14'th Jul 2021
SOUTH SAN FRANCISCO, Calif., July 14, 2021 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), today announced that data from its clinical development program for TAVALISSE® (fostamatinib dis
Top Biotech Penny Stocks to Buy This Week? 9 To Watch
02:35pm, Tuesday, 06'th Jul 2021
Biotech penny stocks continue to climb, which companies are on your watchlist? The post Top Biotech Penny Stocks to Buy This Week?
Fostamatinib Selected for NIH ACTIV-4 COVID-19 Clinical Trial
07:30am, Tuesday, 29'th Jun 2021
SOUTH SAN FRANCISCO, Calif., June 29, 2021 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), today announced that fostamatinib, the Company's novel oral spleen tyrosine kinase (SYK) inhibito
